Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction

Annals of Medicine

Volumn 34, Issue 7-8, 2002, Pages 514-522

  Dauterman, Kent ^a   Topol, Eric ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute myocardial infarction; Fibrinolysis; Guidelines; Reperfusion; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HIRUDIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM; NITRATE; POTASSIUM; PROSTAGLANDIN SYNTHASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN; THROMBIN INHIBITOR; THROMBOXANE A2; TICLOPIDINE; UNINDEXED DRUG;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; DRUG CONTRAINDICATION; FIBRINOLYTIC THERAPY; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART REHABILITATION; HUMAN; PATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; STRATIFICATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036957937     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902321117724     Document Type: Review

References (62)

1. Ryan TJ, Amman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at www.acc.org Accessed on January 15, 2002.
2. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-60.
3. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-32.
4. The GUSTO-V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357: 1905-14.
5. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
6. The In-TIME-II Investigators. Intravenous nPA for the treatment of infarcting myocardium early, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-13.
7. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996; 94: 911-21.
8. The HERO-2 Trial Investigators. Thrombin-specific anti-coagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet (in press).
9. De Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38: 11283-94.
10. Ellis SG, Ribeiro da Silva E, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: Insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 2000; 139: 1046-53.
11. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341: 871-8.
12. Wyse DG, Kellen J, Rademaker AW. Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction. J Am Coll Cardiol 1988; 12: 507-13.
13. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2000; 102(suppl I): I1-384.
14. Yusuf S, Sleight P, Rossi P, Ramsdale D, Peto R, Furze L, et al. Reduction in infarct size, arrhythmias, and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation 1983; 67: 132-41.
15. Norris RM, Barnaby PF, Brown MA, Geary GG, Clarke ED, Logan RL, et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol. Lancet 1984; 2: 883-6.
16. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-8.
17. Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group-ISIS-4. A randomized factorial trial assessing oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
18. Maroko PR, Radvany P, Braunwald E, Hale SL. Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 1975; 52: 360-8.
19. Madias JE, Hood WB Jr. Reduction of precordial ST-segment elevation in patients with anterior myocardial infarction by oxygen breathing. Circulation 1976; 53(suppl I): I198-200.
20. Fillmore SJ, Shapiro M, Killip T. Arterial oxygen tension in acute myocardial infarction: serial analysis of clinical state and blood gas changes. Am Heart J 1970; 79: 620-9.
21. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993; 14(suppl F): 18-25.
22. Thrombolysis in Myocardial Infarction Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-27.
23. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico-GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
24. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction (CONSENSUS II). N Engl J Med 1992; 327: 678-84.
25. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-77.
26. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145-53.
27. Lee KL, Woodlief L, Topol EJ, Weaver WD, Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: Results from an international trial of 41,021 patients. Circulation 1995; 91: 1659-68.
28. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-34.
29. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary unit: A two-year experience with 250 patients. Am J Cardiol 1967; 20: 457-64.
30. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
31. Jollis JG, DeLong ER, Peterson ED, Muhlbaier LH, Fortin DF, Califf RM, et al. Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med 1996; 335: 1880-7.
32. Nash IS, Nash DB, Fuster V. Do cardiologists do it better? J Am Coll Cardiol 1997; 29: 475-8.
33. Ayanian JZ, Guadagnoli EG, McNeil BJ, Cleary PD. Treatment and outcomes of acute myocardial infarction among patients of cardiologists and generalist physicians. Arch Intern Med 1997; 157: 2570-6.
34. Goldman L. The value of cardiology. N Engl J Med 1996; 335: 1918-9.
35. Go AS, Rao RK, Dauterman KW, Massie BM. A systematic review of the effects of physician specialty on the treatment of coronary disease and heart failure in the United States. Am J Med 2000; 108: 216-26.
36. Frances CD, Go AS, Dauterman KW, Deosaransingh K, Jung DL, Gettner S, et al. Outcome following acute myocardial infarction: Are differences among physician specialties the result of quality of care or case mix? Arch Intern Med 1999; 159: 1429-36.
37. Moss AJ, Zareba W, Hall J, Klein H, Wilber DJ, Cannom DS, et al. for the MADIT 2 Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
38. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-97.
39. The 4S Investigators. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
40. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. for the CARE Investigators. Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
41. The long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
42. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-8.
43. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285: 1585-91.
44. The Heart Protection Study Collaborative Group. MRC/BHF Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
45. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial. Lancet 2000; 355: 337-45.
46. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI-16) trial. Circulation 2000; 102: 149-56.
47. The BRAVO (Blockade of the GP IIb/IIIa Receptor to Avoid Vascular Occlusion) Investigators. To assess the effects of lotrafiban, an oral glycoprotein IIb/IIIa blocker, combined with aspirin in patients with cardiovascular or cerebrovascular disease. Am Heart J 2000; 139: 927-33.
48. The CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
49. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
50. Fiore LK, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105: 557-63.
51. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350: 389-96.
52. Warfarin Reinfarction Study II (WARIS II), presented at the European Society of Cardiology, Stockholm, 2001.
53. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
54. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-74.
55. Cairns JA, Connolly SJ, Roberts R, and Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-82.
56. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341: 1882-90.
57. Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000; 342: 1937-45.
58. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
59. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Bittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-13.
60. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
61. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
62. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.